Shifting Focus From Dx Development, Quanterix Aims to Launch Commercial SiMoA Instrument in 2013
February 25, 2011
Shifting Focus From Dx Development, Quanterix Aims to Launch Commercial SiMoA Instrument in 2013
The firm is currently developing a research-use-only version of the instrument that it expects to launch in 2013 with an FDA-approved version coming sometime after that. It plans to manufacture the RUO device through an outside vendor because most of its parts are off-the-shelf.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study Shows Quanterix's Single Molecule Array Assay Measures PSA at Previously Undetectable Levels
June 11, 2010 / ProteoMonitor - Quanterix and Sony DADC Ink Co-Development Deal for SiMoA Consumables
July 22, 2011 / ProteoMonitor - Quanterix, Gothenberg Researchers Show Potential Link Between Heart Attacks and Alzheimer's Marker
April 15, 2011 / ProteoMonitor - Quanterix Raises $2.5M in Financing Round Targeting $5M
October 15, 2010 / ProteoMonitor - Quanterix's AccuPSA Test Predicts Five-Year Recurrence-Free Survival in Prostate Cancer Study
October 21, 2011 / ProteoMonitor